Follow The Filings

BIO Bio Rad Labs Inc.

Health Care, filed as BIO RAD LABS INC (CL A), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 3 Owners
  • Max 2.4%
  • $1.1B
  • 1 exit 3 small

In 2026 Q2 Mason Hawkins sold out of Bio Rad Labs.

Who owns this now

Largest portfolio weights among holders, up to 2.4% (John Rogers, Ariel Investments). Not free-float ownership.

  1. John Rogers Add 2.4%
  2. First Pacific Advisors Reduce 1.5%
  3. First Eagle Investment Manage... Add 1.3%

Who owns BIO

Sorted by value, long equity only, as of 2026 Q2.

History
First Eagle Investment Management 1.3%, was 1.2% Small add +0.1% 2,606,219 $765M History
John Rogers, Ariel Investments 2.4% Small add +3.9% 816,751 $240M History
First Pacific Advisors 1.5%, was 1.6% Small trim −1.3% 401,861 $118M History
Mason Hawkins, Southeastern Asset Management exited 2026 Q2 Last 2026 Q1 2.2% Exit −2.23% 162,804 $45M History

3 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BIO insider trades
  • None no insider bought on the open market
  • $350K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Eva Anette Engelhardt EVP, President, CDG
    Sale
    $136K 550 shares at $246.54 61% of stake
    Traded May 11 Filed May 13
    ↗
  2. James Barry EVP, President, LSG
    Sale
    $214K 700 shares at $306.18 58% of stake
    Traded Nov 6, 2025 Filed Nov 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 29 option exercises and 25 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 2.02,2.05,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A DEFINITIVE PROXY STATEMENT Filing Doc
8-K 7.01 Filing Doc
10-K Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.67B $2.57B $2.58B
Gross profit $1.43B $1.38B $1.34B
Gross margin * 53.4% 53.7% 51.9%
Net income -$0.637B -$1.84B $0.76B
Net margin * -23.9% -71.9% 29.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $3.05B $3.03B $2.91B
Total non-current assets * $9.25B $6.33B $7.67B
Total assets $12.3B $9.36B $10.58B
Total current liabilities $522.8M $467.8M $517M
Total non-current liabilities * $3.04B $2.33B $2.61B
Total equity $8.74B $6.57B $7.45B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $374.94M $455.2M $532.2M
Cash from investing $20.21M -$160.2M -$189.7M
Cash from financing -$425.65M -$218.8M -$283.2M
Net change in cash -$30.18M $85.4M $42.4M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.